Besides PSA, detecting a panel of other biomarkers, such as hk2, urokinase Plasminogen Activator (uPA) and its receptor (uPAR), TGFβ, IL6, IL6R, Ki-67, ERK5, and DRE may improve PCa diagnosis, staging, prognosis and monitoring 4. This evidence concerns the gene IL6 and posterior cortical atrophy.